 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...7273747576777879808182...123124» |
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] NOVEL SERUM BIOMARKERS USEFUL FOR DRUG SELECTION OF SORAFENIB AND LENVATINIB FOR HEPATOCELLULAR CARCINOMA. () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1313;
We identified novel biomarkers that may be useful in selecting appropriate drugs for SFN or LEN . We plan to conduct the validation in a large number of cases and create a discriminant formula .
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] LEVOCARNITINE INHIBITS PRESARCOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1305;
In patients with HCC, levocarnitine restores serum levels of carnitine and inhibits presarcopenia induced by LEN treatment . It might also inhibit protein catabolism in patients with HCC treated by LEN .
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] INVOLVEMENT OF FGF AND VEGF SIGNALING IN MULTI- KINASE INHIBITOR RESISTANCE IN HEPATOCELLULAR CARCINOMA () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1302;
Background: The approval of atezolizumab in combination with bevacizumab as first-line therapy for advanced hepatocellular carcinoma has brought about a major paradigm shift, but sequential therapy has become the mainstay after first-line treatment. The results suggest that the effects of FGF and VEGF signaling on sorafenib and lenvatinib resistance may be different .
- Avastin (bevacizumab) / Roche
[VIRTUAL] INFLUENCE OF LENVATINIB ON HOST IMMUNITY IN PATIENTS WITH CHRONIC LIVER INJURY AND HEPATOCELLULAR CARCINOMA STRATIFIED BY ETIOLOGY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1300;
Lenvatinib might induce activation of Kupffer cells in stage II or III diseases, although they were not shown in advanced stage . Furthermore, in the evaluation by etiology, Th1 cells significantly increased after treatment in the HCV group compared before treatment, although there was no significant difference in Th2 cells between before and after treatment .
- Avastin (bevacizumab) / Roche
[VIRTUAL] GERIATRIC ASSESSMENT OF ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA PREDICTS WORSENING OF ALBI SCORE WITH MOLECULAR TARGETED THERAPY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1287;
In addition, CGA may predict worse ALBI score in atezolizumab plus bevacizumab treatment . Reducing the starting dose individually based on the results of CGA would be proposed .
- lenvatinib / Generic mfg.
[VIRTUAL] EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1276;
Combination of lenvatinib with different anti-PD-1 antibody demonstrated an efficient efficacy and safety in patients with unrecestable hepatocellular carcinoma . Combination of lenvatinib with pembrolizumab or sintilimab showed better short-term clinical outcome with better ORR and DCR than combined with camrelizumab, which requires a large sample of randomized controlled trial to confirm.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] EFFECTIVENESS OF LENVATINIB VERSUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATIC DECOMPENSATION () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1275;
Combination of lenvatinib with pembrolizumab or sintilimab showed better short-term clinical outcome with better ORR and DCR than combined with camrelizumab, which requires a large sample of randomized controlled trial to confirm. The effectiveness of lenvatinib and sorafenib was comparable for the treatment of unresectable HCC in decompensated patients .
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] DEB-TACE COMBINED WITH HAIC COULD BE AFFORDABLE TREATMENT OPTION FOR ADVANCED STAGE OF HCC () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1263;
ORR and OS after receiving Ultra-FP therapy were remarkable in comparison to various kinds of systemic therapy including MTA and iCIs . The maintaining of liver reserve might contribute to the indication of various kinds of treatment as the next choice .
- lenvatinib / Generic mfg.
[VIRTUAL] COMPARISON OF LENVATINIB AND HEPATIC ARTERIAL INFUSION CHEMOTHERAPY ON THE EFFICACY AND SAFETY IN UNRESECTABLE HCC: A MULTI-CENTER, PROPENSITY SCORE ANALYSIS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1258;
The maintaining of liver reserve might contribute to the indication of various kinds of treatment as the next choice . Lenvatinib is comparable to HAIC in terms of ORR and OS in selected patients with unresectable HCC .
- lenvatinib / Generic mfg.
[VIRTUAL] CLINICAL APPLICATION OF LENVATINIB COMBINED WITH PD-1 INHIBITOR AND TACE IN CONVERSION THERAPY FOR PATIENTS WITH ADVANCED/NON-RESECTABLE LIVER CANCER () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1255;
PD-1 inhibitors included Camrelizumab,Sintilimab, Pembrolizumab,Toripalimab . The combination therapy of lenvatinib, PD-1 inhibitor and TACE can be reviewed as a reasonable and promising conversion therapy option for advanced/non- resectable liver cancer with safety and effectiveness .
- lenvatinib / Generic mfg.
[VIRTUAL] CIRCULATING CELL-FREE TUMOR DNA ANALYSIS IN ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1252;
The current study demonstrated that somatic alterations could be detected in the majority of advanced HCC patients by ctDNA profiling and that ctDNA-kinetics during lenvatinib treatment was a useful marker of disease progression . These results suggest that ctDNA profiling is a promising method that provides valuable information in clinical practice .
- lenvatinib / Generic mfg.
[VIRTUAL] DIFFERENCES IN THE INTESTINAL MICROBIOME ASSOCIATED WITH DIARRHEA DURING LENVATINIB TREATMENT FOR HEPATOCELLULAR CARCINOMA () - Oct 21, 2021 - Abstract #AASLD2021AASLD_815;
These results suggest that ctDNA profiling is a promising method that provides valuable information in clinical practice . Differences in the intestinal microbiomes and their functions may influence the incidence of diarrhea during lenvatinib treatment .
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] FGFR INHIBITION ALTERS ‘COLD TUMOR’ INTO ‘HOT TUMOR’ IN IMMUNE SYNGENEIC ORTHOTOPIC HEPATOCELLULAR CARCINOMA () - Oct 21, 2021 - Abstract #AASLD2021AASLD_685;
In the orthotopic xenograft mice model for HCC, lenvatinib and AZD4547, which commonly inhibit FGFR signaling, altered TIME from ‘cold’ to ‘hot’. The findings obtained from this study support the therapeutic concept of combining drugs targeting angiogenesis with ICIs .
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) (clinicaltrials.gov) - Oct 20, 2021
P2, N=10, Recruiting, Sponsor: National University Hospital, Singapore
The findings obtained from this study support the therapeutic concept of combining drugs targeting angiogenesis with ICIs . Not yet recruiting --> Recruiting
- || lenvatinib / Generic mfg.
Clinical, Journal: Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma. (Pubmed Central) - Oct 20, 2021
Maintaining high 2M-DBR of lenvatinib is essential to increase response rate and PFS. To achieve high 2M-DBR levels, preservation of pre-treatment BTR is essential, suggesting the importance of nutritional management in the treatment for hepatocellular carcinoma with lenvatinib.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, HEOR: Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. (Pubmed Central) - Oct 20, 2021
To achieve high 2M-DBR levels, preservation of pre-treatment BTR is essential, suggesting the importance of nutritional management in the treatment for hepatocellular carcinoma with lenvatinib. Given the use of Japan-specific data in the cost-effectiveness model, it is expected that the use of lenvatinib as a first-line treatment in Japan will be associated with cost savings and improved clinical outcomes versus sorafenib for patients with unresectable HCC.
- || lenvatinib / Generic mfg.
Clinical, Clinical data, Journal: Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. (Pubmed Central) - Oct 20, 2021
Baseline M2BPGi levels may predict the tolerability and treatment response to lenvatinib. Patients with high M2BPGi levels may less likely to benefit from lenvatinib therapy.
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: approvalsWatch: The EMA has granted a positive opinion for the first-line use of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma. More details on the decision & supporting research by @motzermd et al here @uroupdate @EMA_News https://t.co/zOC6tFx7ZR (Twitter) - Oct 19, 2021
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 18, 2021
P1b, N=104, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Patients with high M2BPGi levels may less likely to benefit from lenvatinib therapy. Trial completion date: Aug 2021 --> Sep 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 18, 2021
P1, N=24, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Aug 2021 --> Sep 2022 Recruiting --> Active, not recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date: CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 18, 2021
P3, N=634, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Jan 2025
- || Bavencio (avelumab) / EMD Serono
New P1 trial, Combination therapy: MS100070_0087: Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors (clinicaltrials.gov) - Oct 17, 2021
P1, N=50, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Kidney Pathology Findings in Patients with AKI Associated with Tyrosine Kinase Inhibitors () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1367;
Results We identified 13 cancer patients treated with Sunitinib, Cabozantinib, Lenvatinib, Regorafenib, Erlotinib, Osimertinib and Ibrutinib between 2018-2020 and developed acute kidney injury (AKI) attributed to possible TKI nephrotoxicity...Urine analysis was not predictive of the kidney pathology. Treating nephrotoxicity by discontinuation of the offending TKI was associated with partial kidney recovery, however patients had poor overall prognosis.
- |||| lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Clinical: Cabozantinib demonstrated a sustained benefit in PFS vs placebo in pts with previously treated, radioactive iodine–refractory differentiated thyroid cancer, regardless of exposure to sorafenib or lenvatinib. @Ja_Capdevila @vallhebron @myESMO #ESMO21 #hncsm https://t.co/zTH7dM612O (Twitter) - Oct 16, 2021
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Retrospective data, Review, Journal: Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. (Pubmed Central) - Oct 16, 2021
The tyrosine kinase inhibitors (TKIs) sorafenib, lenvatinib, vandetanib, and cabozantinib are currently used for thyroid cancer treatment; however, the differences in their clinical efficacy and toxicity remain unclear...Although TKIs are promising agents for thyroid cancer treatment, they are unlikely to lead to a cure. Thus, even in the TKI era, a multimodal treatment including surgery, radioiodine therapy, external beam radiotherapy, and TKIs is required to optimize patient chances of improved survival.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone (clinicaltrials.gov) - Oct 15, 2021
P2, N=5, Suspended, Sponsor: Thomas Jefferson University
Thus, even in the TKI era, a multimodal treatment including surgery, radioiodine therapy, external beam radiotherapy, and TKIs is required to optimize patient chances of improved survival. Trial primary completion date: May 2021 --> May 2022
- | lenvatinib / Generic mfg.
Preclinical, Journal: UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies. (Pubmed Central) - Oct 15, 2021
An UPLC -MS/MS method that can be used for studying drug-drug interaction as a valuable tool was developed in this study. Drug-drug interactions were observed between the WZC and LEN.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, IO biomarker, Metastases: A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients (clinicaltrials.gov) - Oct 14, 2021
P2, N=35, Not yet recruiting, Sponsor: Shanghai Chest Hospital
- || E7386 / Eisai, PRISM Pharma
Enrollment change: E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov) - Oct 14, 2021
P1b, N=61, Recruiting, Sponsor: Eisai Inc.
Drug-drug interactions were observed between the WZC and LEN. N=42 --> 61
- |||||||||| EG-007 / Evergreen Therap
New P3 trial, Head-to-Head, Metastases: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (clinicaltrials.gov) - Oct 14, 2021
P3, N=450, Not yet recruiting, Sponsor: Evergreen Therapeutics, Inc.
- || fostroxacitabine bralpamide (MIV-818) / Medivir
Enrollment closed, Trial completion date, Trial primary completion date: MIV-818-101: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations (clinicaltrials.gov) - Oct 14, 2021
P1/2, N=102, Active, not recruiting, Sponsor: Medivir
N=42 --> 61 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), everolimus / Generic mfg., lenvatinib / Generic mfg.
FDA event: Lenvatinib + pembrolizumab or everolimus for advanced #RenalCellCarcinoma, the #CLEAR trial #JournalClub. @WallisCJD @UofT & @zklaassen_md @GACancerCenter discuss data from the study leading to the recent @US_FDA approval. #WatchNow > https://t.co/5fasGC7HWU @motzermd @NEJM (Twitter) - Oct 12, 2021
- || Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. (Pubmed Central) - Oct 12, 2021
Besides the targeted therapy, more aggressive treatment modalities have been proposed and practiced in the clinic which may improve the prognosis of HCC patients with PVTT and prolong the patients' survival time, such as transarterial chemoembolization, radiotherapy, hepatic resection, liver transplantation, and various combination therapies. Herein, we aim to review and summarize the advances in the treatment of HCC with PVTT.
- quavonlimab/pembrolizumab (MK-1308A) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD)
MK-1308A + lenvatinib and pembrolizumab + belzutifan + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for clear cell renal cell carcinoma: randomized, open-label, phase 3 study () - Oct 12, 2021 - Abstract #KCRS2021KCRS_51;
P3
Primary end points will be assessed in arm A compared with arm C and in arm B compared with arm C for patients with IMDC intermediate/poor status and in all patients regardless of IMDC status. Secondary end points are objective response rate, duration of response, patient-reported outcomes, and safety.
- Welireg (belzutifan) / Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Randomized, open-label, phase 3 study of belzutifan plus lenvatinib versus cabozantinib in patients with advanced renal cell carcinoma after anti–PD-1/PD-L1 therapy () - Oct 12, 2021 - Abstract #KCRS2021KCRS_50;
P3
Secondary objectives are objective response rate and duration of response per RECIST v1.1 by blinded independent central review and safety. The study is enrolling or planning to enroll at sites in Asia, Australia, Europe, North America, and South America.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab with lenvatinib in the first-line setting for non–clear cell renal cell carcinoma: Openlabel, phase 2 KEYNOTE-B61 study () - Oct 12, 2021 - Abstract #KCRS2021KCRS_49;
P2
Secondary efficacy end points for the study are clinical benefit rate, disease control rate, duration of response, progression-free survival, overall survival, and safety. The study is enrolling or planning to enroll in countries in Asia, Australia, Europe, and North America.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study) () - Oct 12, 2021 - Abstract #KCRS2021KCRS_42;
The OS benefit observed with lenvatinib + pembrolizumab versus sunitinib was maintained at a longer follow-up point. Moreover, OS favored lenvatinib + pembrolizumab in patients with MSKCC or IMDC intermediate or poor risk.
- || lenvatinib / Generic mfg.
Clinical, Journal: Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity. (Pubmed Central) - Oct 10, 2021
To achieve OR and SD for a favorable outcome of first- or later-line LEN, high and moderate early-phase RDI are required, respectively. The degree of RDI during LEN and tolerance need compatible by dose modifications.
- || lenvatinib / Generic mfg.
Review, Journal: Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. (Pubmed Central) - Oct 9, 2021
However, no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear. In this review, we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice.
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical, Monotherapy: @neerajaiims how would you proceed with a patient treated with pembro+lenva that after an intense colitis (clearly due to lenvatinib), suffers from a bowel diverticulum perforation? Reduce TKI doses? Pembrolizumab in monotherapy? Change treatment line?? Thank you! (Twitter) - Oct 8, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical, Monotherapy: @DrChoueiri how would you proceed with a patient treated with pembro+lenva that after an intense colitis (clearly due to lenvatinib), suffers from a bowel diverticulum perforation? Reduce TKI doses? Pembrolizumab in monotherapy? Change treatment line?? Thank you! (Twitter) - Oct 8, 2021
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Updated OS HR for Lenvatinib & Pembro in latest update is now 0.72. We saw similar results with longer follow up with axi/Pembro 0.73. The drift in OS occurs with all these combos. OS data in good risk remains uncertain across VEGF-IO combos but remains the SOC. #KCRS21 (Twitter) - Oct 8, 2021
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg., Sutent (sunitinib) / Pfizer
P3 data: #KCRS21 @DrChoueiri presents the first OS update of the phase 3 Clear study of Lenvatinib +pembrolizumab vs sunitinib in mRCC #kidneycancer : HR: 0.72 continues to strongly favor the combo. @OncoAlert @urotoday @kidneycan (Twitter) - Oct 8, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Great to see the follow up OS data from #CLEAR trial by the amazing @DrChoueiri! Lenvatinib w pembro is very active. @kidneycan @KidneyCancer @kcCURE #KCRS21mobty (Twitter) - Oct 8, 2021
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Targeted therapy for hepatocellular carcinoma. (Pubmed Central) - Oct 8, 2021
Over the same period combination therapies, including anti-angiogenesis agents with ICIs, dual ICIs and targeted agents in conjunction with surgery or other loco-regional therapies, have been extensively investigated and have shown promise and provided the basis for exciting clinical trials. Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance, with the goal of improving the survival of patients with HCC.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: LEAP-001 China Extension: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (clinicaltrials.gov) - Oct 7, 2021
P3, N=875, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance, with the goal of improving the survival of patients with HCC. Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
- Sutent (sunitinib) / Pfizer
Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) + everolimus (E) vs sunitinib (S) treatment arms () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1210;
Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 In CLEAR, L+E met the primary endpoint of a significant benefit in PFS vs S. The results of these exploratory analyses suggest that subsequent anticancer medication affected the OS outcome results for L+E vs S in the CLEAR study
- ||| lenvatinib / Generic mfg.
Clinical: Agreed , 25% discontinued Lenvatinib due to toxicities , still impressive results. Definitely needs close outpatient monitoring for optimizing effectiveness. (Twitter) - Oct 7, 2021